Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Within the broader context of the pharmaceutical i
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
For the first time in its chronicle, the pharmaceu
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
The vaccine candidate, which has been licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a complete dose, in contrast to a two full-dose regime, though more work needs to be done to affirm the outcome.
The details from the Phase I/II clinical trials released on December 17 made no reference to the half-dose/full-dose regime, which Oxford has said had been”unplanned” but accepted by regulators.
The university said it had explored two dosing regimes in early stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible”dose sparing” strategy.
“The booster doses of the vaccine are both shown to induce stronger antibody responses than one dose, the conventional dose/standard dose inducing the ideal response,” the university said in a statement.
